Lozenge for treating sore throat, hoarseness and associated dry cough, and inflammatory diseases of the oral and pharyngeal cavity

Abstract

The present invention relates to a pharmaceutical formulation containing a combination of (a) at least one astringent active substance and (b) at least one mucilaginous drug and the use thereof for the prevention or treatment of inflammatory diseases of the oropharyngeal region and for the treatment of painful irritations of the mucosa in the oropharyngeal region and associated irritable cough.

Description

[0001]The present invention relates to a pharmaceutical formulation containing a combination of (a) at least one astringent active substance and (b) at least one mucilaginous drug and the use thereof for the prevention or treatment of inflammatory diseases of the oropharyngeal cavity and for treating painful irritations of the mucosa in the oropharyngeal region and irritable cough associated therewith.BACKGROUND TO THE INVENTION[0002]The present invention relates to a pharmaceutical composition in the form of a formulation suitable for sucking, the composition containing a combination of at least one astringent active substance with at least one second mucilaginous drug or an extract thereof, for the treatment of, in particular, irritations and inflammatory diseases of the oropharyngeal cavity, dry mouth and cough.[0003]The oral mucosa serves particularly to protect the underlying tissue and acts as a natural barrier against mechanical injuries (lesions) and against the penetration ...

AI Technical Summary

Benefits of technology

The present invention relates to a pharmaceutical formulation containing a combination of an astringent active substance and a mucilaginous drug for the prevention and treatment of inflammatory diseases of the oropharyngeal cavity, such as inflammation of the tonsil and pharyngeal lining. The combination can also be used for temporary treatment of painful irritations of the oropharyngeal mucosa and associated cough. The use of the pharmaceutical formulation results in a highly effective and well-tolerated treatment with minimal side effects. The invention is based on physical processes and the combination of astringent and mucilaginous drugs has been found to unexpectedly increase their effectiveness.

Problems solved by technology

Cold, dry or overheated room air as well as alcohol or nicotine adversely affect the normal function of the mucosa and may lead to mucosal irritation, hoarseness, sore throat and dry cough.

Under these circumstances, bacterial colonisation is promoted and pulmonary infections may result.

These frequently involve pain symptoms that are unpleasant for the patient and cause difficulty in swallowing.

Inflammations of the oral cavity e.g., gingivitis, stomatitis or oral mucosal lesions have symptoms that are unpleasant for the patient affected.

A disadvantage of this active substance is the fact that at high doses and if consumed to excess it may cause gastrointestinal problems, breathing difficulties and increased methaemoglobin formation, particularly in children.

When used long-term or in high doses, once again gastrointestinal disorders may result or there may be gustatory irritations.

A disadvantage is the feeling of a dry mouth caused by the astringent effect.

Generally, these active substances are used in the form of monopreparations, but do not always achieve the desired success.